Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
10/8/24 | Stealth Biotherapeutics | Elamipretide (Systemic Delivery) for Cardiomyopathy - Dilated | Subscribers Only | Subscribers Only | Subscribers Only |
10/8/24 | Merck (MRK) | Keytruda for Head and Neck Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
9/27/24 | Johnson (JNJ) | Darzalex Faspro for Multiple Myeloma (MM) | Subscribers Only | Subscribers Only | Subscribers Only |
9/26/24 | AbbVie (ABBV) | Tavapadon for Parkinson's Disease (PD) | Subscribers Only | Subscribers Only | Subscribers Only |
9/26/24 | Enanta (ENTA) | EDP-323 for Respiratory Syncytial Virus (RSV) Treatment | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
09/12/24 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
09/30/24 | Subscribers Only | Subscribers Only | Trial Data - Top-Line Results |
09/30/24 | Subscribers Only | Subscribers Only | Trial Announcement - Other |
09/30/24 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation (Emerging Markets) |
09/30/24 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |